KOTOBUKI PHARMACEUTICAL CO.
Kotobuki Pharmaceutical Co.,Ltd., develops and manufactures drugs and medical supplies. It offers various prescription drugs, such as tablets, granules, creams, capsules, combination tablets, solutions, generic drugs, gastritis, gastric ulcer, and duodenal ulcer therapeutic agents. It also offer antihypertensive agents, Type 2 diabetes therapeutic agents, and cholesterol absorption inhibitors. The company was founded in 1949 and is based in Hanishina, Japan.
KOTOBUKI PHARMACEUTICAL CO.
Industry:
Manufacturing Medical Pharmaceutical Therapeutics
Founded:
1949-01-01
Address:
Nishina, Shizuoka, Japan
Country:
Japan
Website Url:
http://www.ssl.kotobuki-pharm.co.jp
Status:
Active
Contact:
81 268 82 2211
Technology used in webpage:
Google Analytics Apple Mobile Web Clips Icon Google Tag Manager Google Universal Analytics Font Awesome Global Site Tag Sitelinks Search Box Organization Schema ReCAPTCHA ReCAPTCHA V2
Similar Organizations
Darou Pakhsh Pharmaceutical
Darou Pakhsh Pharmaceutical is a manufacturer, supplier and distributor of medical products
JW Pharmaceutical
JW Pharmaceutical is engaged in the manufacturing and distribution of Korean medicine and medical supplies.
Official Site Inspections
http://www.ssl.kotobuki-pharm.co.jp
- Host name: sv359.xbiz.ne.jp
- IP address: 183.90.231.140
- Location: Osaka Japan
- Latitude: 34.6848
- Longitude: 135.5142
- Timezone: Asia/Tokyo
- Postal: 543-0062
More informations about "Kotobuki Pharmaceutical Co."
Company Outline– Kotobuki pharmaceutical Co., Ltd.–
Apr 12, 2020 Company Name Kotobuki Pharmaceutical Co., Ltd. Headquar. 198, Higashigawara, Kamigomyo, Sakaki-machi, Hanishina-gun, Nagano, 389-0697, JapanSee details»
Kotobuki pharmaceutical Co., Ltd.
Jun,14 2024 Newly-marketed drug Zonisamide OD Tablets 2. MARZULENE-S (China name: 麦滋林 TM) for the treatment of gastritis and ulcer exported to China has been certified as an …See details»
Kotobuki’s History;– Kotobuki pharmaceutical Co., Ltd.–
・Through a Cabinet announcement, the new and old fonts “Kotobuki Pharmaceutical Co., Ltd.” and “Trademark Registration No. 6086766” came to be widely used. 1982 ・Tsuyoshi Tomiyama took office as president. 1983 …See details»
Kotobuki Pharmaceutical Co. Ltd. - Drug pipelines, Patents, Clinical ...
Explore Kotobuki Pharmaceutical Co. Ltd. with its drug pipeline, therapeutic area, technology platform, 5 news, and 21 literature, Disease Domain:Endocrinology and Metabolic Disease, …See details»
Kotobuki Pharmaceutical Co. - Crunchbase Company Profile
Kotobuki Pharmaceutical Co.,Ltd., develops and manufactures drugs and medical supplies. It offers various prescription drugs, such as tablets, granules, creams, capsules, combination …See details»
Kotobuki pharmaceutical - VentureRadar
Website: https://ssl.kotobuki-pharm.co.jp/ Develops new pharmaceuticals using advanced technologies and comprehensive studies to produce effective drugs with minimal side effects. …See details»
KOTOBUKI PHARMACEUTICAL CO.,LTD. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for KOTOBUKI PHARMACEUTICAL CO.,LTD. of HANISHINA-GUN, NAGANO. Get the latest business …See details»
Kotobuki Pharmaceutical - Overview, News & Similar companies
Kotobuki Pharmaceutical contact info: Phone number: +81 268822211 Website: www.kotobuki-pharm.co.jp What does Kotobuki Pharmaceutical do? Kotobuki Pharmaceutical Co. Ltd is a …See details»
Kotobuki Pharmaceutical Co., Ltd., 198, Kamigomyo, - Kompass
Presentation - Kotobuki Pharmaceutical Co., Ltd. Manufacturer of pharmaceutical products. Executives - Kotobuki Pharmaceutical Co., Ltd. Buy the executives list from same sectorSee details»
News | Astellas Pharma Inc.
Jan 11, 2018 For more information, please visit our website at https://ssl.kotobuki-pharm.co.jp/en/ Cautionary Notes (Astellas) In this press release, statements made with …See details»
Greetings– Kotobuki pharmaceutical Co., Ltd.–
Our policies for development of these chemical entities are to promote co-research, co-development, co-promotion and licensed-out, positively. ... We, KOTOBUKI, continue to put …See details»
Kotobuki Pharmaceutical - Products, Competitors, Financials, …
Kotobuki Pharmaceutical focuses on the development and manufacturing of pharmaceutical products within the healthcare sector. The company specializes in the entire production …See details»
Full List of Pharmaceutical Companies in Japan (2024)
Nov 17, 2022 GlaxoSmithKline K.K. 1-8-1 Akasaka, Minato-ku, Tokyo 107-0052,Japan Phone: +81 3-4231-5000 https://www.gsk.com. GlyTech, Inc. 134 Chudoji Minamimachi KRP#1-2F, …See details»
Kotobuki Pharmaceutical Co. Reviews | Read Client Reviews of …
Read reviews of Kotobuki Pharmaceutical Co.. Write and share your personal story. Your experience will help others make the right buying decision. ... Search. Kotobuki …See details»
Inquiry– Kotobuki pharmaceutical Co., Ltd.–
Name Country Organization name (Company, Institution, School etc.) Department name (none) Phone including country code Your Email Inquiry Please do not input personal information …See details»
Ozmosi | KT6-971 Drug Profile
KT6-971 Alternative Names: kt6-971, kt6971, s-556971, s556971, s 556971 Latest Update: 2015-06-12 Latest Update Note: Clinical Trial UpdateSee details»
Kotobuki Pharm. Improved Business by Outsourcing Distribution
Kotobuki Pharmaceutical Co., Ltd., a Sapporo-based wholesaler specializing in generic drugs, has improved its business results by outsourcing distribution. In August 2003, it outsourced …See details»
CSR (Corporate Social Responsibility) Management - kotobuki …
CSR（Corporate Social Responsibility）～Aiming for a compa. We aim to minimize losses to the natural environment and the social environment as much as possible, aim for “Sustainable …See details»
EGUALEN SODIUM HYDRATE - National Center for Advancing …
Egualen is an azulene derivative developed for the treatment of peptic ulcer and marketed in Japan under the tradename Azuloxa. The drug exerts its antiulcer activity by antagonizing …See details»
New Drug Development– Kotobuki pharmaceutical Co., Ltd.–
1: ASP2215 （giliteritinib） ①Development stage：Global/Phase Ⅲ ②Target：Acute myeloid leukemia ③Development：Astellas: 2: S-556971（KT6-971）: ①Development …See details»